This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.
The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.
Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Procoralan (ivabradine) from Servier in July.
a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has obtained US rights to for an upfront fee of $50m plus undisclosed future milestones and royalties
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...